BRIEF-The U.S. FDA Granted Fast Track Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

Reuters08-06

BRIEF-The U.S. FDA Granted <a href="https://laohu8.com/S/FTRK">Fast Track</a> Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

Aug 6 (Reuters) - Dizal Pharmaceutical Co Ltd 688192.SS:

THE U.S. FDA GRANTED FAST TRACK DESIGNATION TO DIZAL'S BIRELENTINIB FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA

Source text: ID:nPn1269pHa

Further company coverage: 688192.SS

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2557370717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557370717","market":"us","top_or_hot":-1,"title":"BRIEF-The U.S. FDA Granted Fast Track Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-The U.S. FDA Granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma</title></head><body><p><span>Aug 6 (Reuters)</span><span> - </span>Dizal Pharmaceutical Co Ltd <span>688192.SS</span>:</p><ul><li><p>THE U.S. FDA GRANTED FAST TRACK DESIGNATION TO DIZAL'S BIRELENTINIB FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA</p></li></ul><p>Source text: <span>ID:nPn1269pHa</span></p><p>Further company coverage: <span>688192.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-The U.S. FDA Granted Fast Track Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-The U.S. FDA Granted Fast Track Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-06 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-The U.S. FDA Granted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma</title></head><body><p><span>Aug 6 (Reuters)</span><span> - </span>Dizal Pharmaceutical Co Ltd <span>688192.SS</span>:</p><ul><li><p>THE U.S. FDA GRANTED FAST TRACK DESIGNATION TO DIZAL'S BIRELENTINIB FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA</p></li></ul><p>Source text: <span>ID:nPn1269pHa</span></p><p>Further company coverage: <span>688192.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUA8M37YL:1","article_id":"2557370717","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557370717","pubTimestamp":1754487948,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-The U.S. FDA Granted Fast Track Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic LymphomaAug 6 (Reuters) - Dizal Pharmaceutical Co Lt","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688192":"迪哲医药","BK0239":"医药制造"},"translate_title":"简报-美国FDA授予Dizal公司的Birelentinib用于复发/难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的快速通道资格","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688192":0.9},"content_text":"BRIEF-The U.S. FDA Granted Fast Track Designation To Dizal's Birelentinib For Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic LymphomaAug 6 (Reuters) - Dizal Pharmaceutical Co Ltd 688192.SS:THE U.S. FDA GRANTED FAST TRACK DESIGNATION TO DIZAL'S BIRELENTINIB FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMASource text: ID:nPn1269pHaFurther company coverage: 688192.SS ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557370717","isCrawlerRequest":true}